Gilead CEO Daniel O’Day saw another rise in his pay in 2024, reflecting the steadily upward trajectory of the company since ...

Gilead Sciences Inc. CEO Daniel O'Day's compensation rose 4.8% last year to $23.7 million — roughly $97 for every buck made ...

News of potential federal budget cuts impacting HIV drugs in the U.S. was quickly reflected in a dip in share prices for top ...

Gilead Sciences stock has room to climb, and investors shouldn’t overlook the company’s impressive record in navigating HIV policy, Citi Research says. Analysts led by Geoff Meacham reiterated a Buy ...

Shares of Gilead Sciences, Inc. dropped nearly 2.5% on Wednesday and extended losses after hours following a report that the ...

While speaking with TooFab at PaleyFest LA, Samira Wiley opened up bout her journey starring as Moira Strand in The ...

Investors with a lot of money to spend have taken a bearish stance on Gilead Sciences GILD. And retail traders should know.

As The Handmaid's Tale gets ready to stream its final season, Samira Wiley reveals to TooFab what it felt like for Moira to ...

Moss brought her baby to the Vancouver set for the sixth and final season of the hit Hulu series, which sees her heroine June ...

The Health and Human Services Department is considering cuts to HIV prevention funding, according to The Wall Street Journal.

Gilead Sciences Inc. closed 10.06% short of its 52-week high of $119.96, which the company achieved on March 10th.

Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Gilead Sciences ...